Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Phase 2

Terminated

Conditions: Inflammation
Rheumatoid Arthritis

Interventions: Drug: placebo
Drug: NNC0109-0012

First Posted Date: 2012-07-10

Last Posted Date: 2018-09-05

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 239

Registration Number: NCT01636817

Locations: 🇬🇧
Novo Nordisk Investigational Site, Wolverhampton, United Kingdom

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate

Phase 2

Terminated

Conditions: Inflammation
Rheumatoid Arthritis

Interventions: Drug: placebo
Drug: NNC0109-0012

First Posted Date: 2012-07-10

Last Posted Date: 2018-09-05

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 298

Registration Number: NCT01636843

Locations: 🇺🇦
Novo Nordisk Investigational Site, Zaporizhzhia, Ukraine

A Multi-centre, Open Labelled, Multiple Dosing Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC 0172-2021 Administered Subcutaneously to Healthy Male Subjects and Haemophilia Subjects

Phase 1

Terminated

Conditions: Haemophilia A
Congenital Bleeding Disorder
Healthy

Interventions: Drug: NNC172-2021

First Posted Date: 2012-06-29

Last Posted Date: 2019-05-15

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 4

Registration Number: NCT01631942

Locations: 🇬🇧
Novo Nordisk Investigational Site, Harrow, United Kingdom

French Observational Survey to Assess Hypoglycaemia in Insulin-treated Diabetic Patients

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1
Diabetes Mellitus, Type 2

Interventions: Drug: insulin

First Posted Date: 2012-06-26

Last Posted Date: 2017-01-19

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 4424

Registration Number: NCT01628341

Locations: 🇫🇷
Novo Nordisk Investigational Site, Paris La défense cedex, France

A Trial Investigating the Absolute Bioavailability of Insulin Degludec in Healthy Subjects

Phase 1

Completed

Conditions: Healthy
Diabetes

Interventions: Drug: insulin degludec

First Posted Date: 2012-06-20

Last Posted Date: 2015-02-19

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 18

Registration Number: NCT01623375

Safety and Tolerability of Liraglutide in Healthy Japanese Volunteers

Phase 1

Completed

Conditions: Diabetes
Healthy

Interventions: Drug: liraglutide
Drug: placebo

First Posted Date: 2012-06-15

Last Posted Date: 2017-01-25

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 24

Registration Number: NCT01620476

Locations: 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan

Pharmacokinetics of Biphasic Insulin Aspart 50 and 70 in Japanese Healthy Volunteers

Phase 1

Completed

Conditions: Diabetes
Healthy

Interventions: Drug: biphasic insulin aspart 50
Drug: biphasic insulin aspart 70

First Posted Date: 2012-06-15

Last Posted Date: 2017-01-05

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 24

Registration Number: NCT01620333

Locations: 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan

Comparison of Insulin Aspart Produced by Current Process and the NN2000 Process in Healthy Japanese

Phase 1

Completed

Conditions: Diabetes
Healthy

Interventions: Drug: biphasic human insulin 30

First Posted Date: 2012-06-15

Last Posted Date: 2017-03-01

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 34

Registration Number: NCT01620450

Locations: 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan

Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Japanese Subjects

Phase 1

Completed

Conditions: Healthy
Diabetes

Interventions: Drug: biphasic insulin aspart 50

First Posted Date: 2012-06-15

Last Posted Date: 2017-02-24

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 30

Registration Number: NCT01620437

Locations: 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan

Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: placebo
Drug: liraglutide

First Posted Date: 2012-06-15

Last Posted Date: 2019-03-19

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 279

Registration Number: NCT01620489

Locations: 🇬🇧
Novo Nordisk Investigational Site, Swansea, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy